Instrument Inactif

Gouvernance XOMA Royalty Corporation NYSE

XOMAP

US98419J3059

Production de spectacles

Comité Exécutif: XOMA Royalty Corporation

Dirigeant

Fonctions occupéesDepuis

Owen Hughes

51 ans

Chief Executive Officer

01/01/2023

Juliane Snowden

Investor Relations Contact

Bradley Sitko

45 ans

Chief Investment Officer

03/01/2023

Maricel Montano

42 ans

General Counsel	01/08/2025
Corporate Secretary	01/08/2025

Jeffrey Trigilio

42 ans

Director of Finance/CFO

12/01/2026

Composition du Conseil d'Administration: XOMA Royalty Corporation

Administrateur	ComitésDepuis

Anciens Dirigeants et Administrateurs: XOMA Royalty Corporation

Insider

Fonctions occupées

DepuisJusqu'au

Joseph Limber

Director/Board Member	13/12/2012	14/07/2026
Independent Dir/Board Member	13/12/2012	14/07/2026

Jack Wyszomierski

Director/Board Member	26/08/2010	-
Chairman	07/01/2024	14/07/2026
Independent Dir/Board Member	26/08/2010	14/07/2026

Thomas Burns

Director of Finance/CFO	03/04/2015	12/01/2026
Corporate Officer/Principal	14/08/2006	03/04/2015

W. van Ness

Director/Board Member	15/12/2021	17/05/2023
Chairman	01/09/2011	15/12/2021
Independent Dir/Board Member	01/09/2011	17/05/2023

James Neal

Director/Board Member	21/12/2016	15/12/2021
Chief Executive Officer	21/12/2016	01/01/2023
Chairman	15/12/2021	01/01/2023
Chief Operating Officer	01/11/2015	21/12/2016
Corporate Officer/Principal	19/11/2009	01/11/2015

Charles C. Wells

Chief Tech/Sci/R&D Officer	01/05/2001	30/06/2017
Human Resources Officer	01/05/2001	30/06/2017

John Varian

Director/Board Member	01/12/2008	01/05/2017
Chief Executive Officer	31/08/2011	21/12/2016

Bill Bowes

Director/Board Member	01/02/1986	05/01/2017
Independent Dir/Board Member	01/02/1986	05/01/2017

Timothy Walbert

Director/Board Member	15/11/2011	01/01/2017
Independent Dir/Board Member	15/11/2011	01/01/2017

Peter Hutt

Director/Board Member	01/05/2005	01/01/2017
Independent Dir/Board Member	01/05/2005	01/01/2017

Patrick Scannon

Director/Board Member	01/01/1993	21/12/2016
Chief Tech/Sci/R&D Officer	27/04/2009	21/12/2016
Founder	07/07/2010	21/12/2016
Corporate Officer/Principal	01/01/1993	27/04/2009

Paul Rubin

Chief Tech/Sci/R&D Officer

08/06/2011

18/11/2016

Fred Kurland

Director of Finance/CFO	28/12/2008	03/04/2015
Corporate Secretary	28/12/2008	03/04/2015

Kelvin Neu

Director/Board Member

19/07/2012

01/01/2015

Thomas Klein

Corporate Officer/Principal

18/03/2013

Christopher J. Margolin

General Counsel	01/01/1991	31/08/2012
Corporate Secretary	01/01/1991	31/08/2012

Steven Engle

Chief Executive Officer	06/08/2007	31/08/2011
Chairman	06/08/2007	31/08/2011
President	06/08/2007	31/08/2011

Charles Fisher

Director/Board Member

01/07/2007

21/02/2011

Patrick Zenner

Director/Board Member

01/05/2002

21/07/2010

Patrick Rivers

Corporate Officer/Principal

01/10/2005

01/01/2009

Stephen Doberstein

Chief Tech/Sci/R&D Officer

07/07/2010

J. Boyle

Director of Finance/CFO

01/01/2005

08/08/2008

James G. Andress

Director/Board Member

01/11/1995

11/03/2008

Mary L. Anderson

Corporate Officer/Principal

01/02/2008

John L. Castello

Chief Executive Officer	01/04/1992	03/08/2007
Chairman	01/04/1992	03/08/2007
President	01/04/1992	03/08/2007

Paul D. Goodson

Public Communications Contact

01/12/2006

Daniel J. Gennevois

Chief Tech/Sci/R&D Officer

01/06/2003

01/07/2006

Ronald H. Carlson

General Counsel

01/01/1999

01/01/2006

Peter B. Davis

Director of Finance/CFO

01/01/1994

01/06/2005

Marc D. Better

Corporate Officer/Principal

01/09/2000

Robert S. Tenerowicz

Chief Operating Officer

01/12/2004

Patricia Donahue

Corporate Officer/Principal

01/01/2004

Clarence L. Dellio

Chief Operating Officer

01/01/1984

01/01/2004

Marilyn A. Lobel

Director of Finance/CFO

01/05/2002

01/12/2003

Calvin L. McGoogan

Corporate Officer/Principal

01/01/2002

Marvin Garrett

Chief Tech/Sci/R&D Officer	01/05/1994	01/06/1999
General Counsel	01/05/1994	01/06/1999

Bo Purtic

Corporate Officer/Principal

01/01/1996

Daniel P. Cafaro

Compliance Officer	01/01/1996	-
General Counsel	01/01/1996	-

Remi Barbier

Corporate Officer/Principal

01/10/1993

01/12/1995

Nadav Friedmann

Chief Tech/Sci/R&D Officer

01/01/1992

01/01/1995

Todd J. Lorenz

Chairman

01/01/1990

01/01/1994

Gary L. Wilcox

Director/Board Member	01/01/1989	01/01/1993
Corporate Officer/Principal	01/01/1989	01/01/1993

Peter Y. Tam

Corporate Officer/Principal

01/01/1991

Steven C. Mendell

Director/Board Member

01/01/1984

Thomas Smart

Corporate Officer/Principal

Ashleigh Barreto

Investor Relations Contact

Lucille W. S. Chang

Corporate Officer/Principal

Mary Haak-Frendscho

Chief Tech/Sci/R&D Officer

Rajneesh Nath

Chief Tech/Sci/R&D Officer

Samuel Saks

Corporate Officer/Principal

James H. Rogers

Corporate Officer/Principal

Kenneth J. Bozzini

Comptroller/Controller/Auditor

Russell T. Kawahata

Corporate Officer/Principal

Bernardus MacHielse

Corporate Officer/Principal

Steven S. Neben

Corporate Officer/Principal

Jay Stoudemire

Corporate Officer/Principal

Arthur Kornberg

Director/Board Member

Dayton T. Reardan

Director/Board Member

Carol DeGuzman

Investor Relations Contact	02/09/2011	-
Public Communications Contact	07/07/2010	-

Richard Richieri

Corporate Officer/Principal

Teresa Berry

Corporate Officer/Principal

Alan M. Solinger

Corporate Officer/Principal

15/06/2011

Lisa Skibsted

Public Communications Contact

09/11/2009

Nicholas Simon

Corporate Officer/Principal

Jeffrey K. Tobias

Chief Tech/Sci/R&D Officer

Lori Kunkel

Corporate Officer/Principal

Arthur C. Louie

Chief Tech/Sci/R&D Officer

Howard Bruce Urnovitz

Corporate Officer/Principal

Thomas C. Ransohoff

Corporate Officer/Principal

Greg Mann

Public Communications Contact

Sean Johnston

Chief Tech/Sci/R&D Officer

J. Michael Hatfield

Corporate Officer/Principal

Distribution de l'Âge des Dirigeants

Parité Homme Femme

Homme	3
Femme	2

Dont comité exécutif

Homme	3
Femme	2

Dont Administrateurs

Homme	0
Femme	0

XOMA Royalty Corporation est une société spécialisée dans la gestion de redevances dans le domaine de la biotechnologie. Son activité de gestion de redevances porte principalement sur des actifs cliniques en phase précoce ou intermédiaire, notamment en phases I et II, présentant un potentiel commercial important et concédés sous licence à des partenaires disposant des moyens financiers nécessaires. La société détient un portefeuille de droits économiques et de redevances liés à des candidats thérapeutiques commerciaux et pré-commerciaux développés en partenariat. Les actifs commerciaux de la société comprennent OJEMDA (tovorafenib), IXINITY, XACIATO, VABYSMO (faricimab svoa), DSUVIA (comprimé sublingual de sufentanil) et MIPLYFFA (arimoclomol). Ses actifs en phase III comprennent le Rilvegostomig (AZD2936), le Ficlatuzumab (AV-299), l’Ovaprene, le D-Fi (FCX-007), le Seralutinib, le Cetrelimab (JNJ-63723283), Ersodetug (RZ358) et Mezagitamab (TAK-079). Ses actifs en phase II comprennent l'Acimtamig (AFM13), l'AFM24, la Vosaroxine, l'Aldoxorubicine, le G03-52-01, le PBF-680, le PBF-677, le Vidutolimod (CMP-001) et le RZ-402. Ses autres actifs comprennent le COM902 et le MT-0169.

Employés

Secteur

Production de spectacles

Plus d'informations sur la société